Global Homocystinuria Market By Symptoms (Myopia, Abnormal Blood Clots, Osteoporosis, Intellectual Disabilities, Seizures, Others) By Diagnosis (Blood and Urine testing, Genetic Testing, Liver Biopsy, X-Rays, Others) By Drug Treatment (Pyridoxine, Betaine, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022– 2030
Industry Trends
Homocystinuria, also known as cystathionine Beta-Synthase deficiency, is an uncommon metabolic disorder characterised by an excess of chemical homocysteine in the urine and blood. CBS deficiency is a disorder caused by a lack of one of many enzymes involved in the conversion of the necessary amino acid methionine to another amino acid (cysteine)–or, less usually, the complex homocysteine to methionine. Enzymes are proteins that help the body's chemical reactions move faster. Certain amino acids are required for optimal growth and development. Homocystinuria is caused by a decrease in the activity of an enzyme called cystathionine beta-synthase, which results in CBS deficiency. For instance, infants with homocystinuria caused by CBS deficiency (also known as classical homocystinuria) may not grow or grow too quickly, have trouble gaining weight at the expected rate (failure to thrive), and experience developmental delays. Homocystinuria is inherited in an autosomal recessive form due to CBS deficiency. Changes (mutations) in a gene that controls the production of the CBS enzyme causes the illness. The vitamin pyridoxine (commonly known as vitamin B6) is required for the CBS enzyme, and some people's diets or supplementation may delay diagnosis by making it more difficult to notice clinically and thus test for it. Moreover leading players in the market are looking forward to developing advanced treatments which has led to the growth of the global homocystinuria market.
In terms of revenue, global homocystinuria market was valued at US$ 56.67 Mn in 2021 growing at a CAGR of 4.0% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Homocystinuria Market Revenue & Forecast, (US$ Million), 2015 – 2030
Symptoms Outlook
Based on the symptoms segment, the global homocystinuria market is segmented into myopia, abnormal blood clots, osteoporosis, intellectual disabilities, seizures and others. The symptoms of homocystinuria caused by CBS deficiency are extremely varied. Some people with the illness may have very minor symptoms, while others may have a wide range of symptoms, including some potentially life-threatening problems. Individuals who respond to pyridoxine medication typically have a milder form of the illness, most likely due to residual CBS enzyme function, although this does not rule out the possibility of life-threatening consequences. Furthermore, the degree of accompanying symptoms in each individual is determined by the presence and precise location of blood clots. Furthermore, infants with homocystinuria due to CBS deficiency appear normal at birth, but if left untreated, they will gradually develop the disorder's symptoms. Homocystinuria has the potential to impact a variety of organ systems across the body. The eyes, central nervous system, skeleton, and the network of vessels that carry blood and other fluids throughout the body are the four organ systems most commonly involved (vascular [circulatory] system). Individuals with homocystinuria due to CBS deficiency have been reported to have additional visual problems.
Drug Treatment Outlook
Homocystinuria caused by CBS deficiency is treated by decreasing homocysteine levels in the blood fluid. A pyridoxine response assessment may be performed first on affected patients. Pyridoxine treatment is helpful in lowering homocysteine and methionine levels in the body in around half of the people who take it. Folate levels must be normal to establish whether a person is responsive to pyridoxine therapy, and some people may need to take folate supplements. The medical community has discovered some people who do not totally respond to pyridoxine therapy with normalisation of homocystinuria measurements. The extent to which these people respond to pyridoxine will determine whether they can be treated with pyridoxine and maybe betaine (a medicine, or if they need a low-protein, low-methionine diet. Individuals with homocystinuria caused by CBS deficiency, particularly those who do not react to pyridoxine medication, may be treated with betaine, a substance that can lower homocysteine levels in the body. Betaine is frequently used as a supplement for those who are on a low-protein, low-methionine diet. The Food and Drug Administration (FDA) has approved Betaine for oral solution (Cystadane) as a therapy for homocystinuria caused by CBS deficiency. It is made by Rare Disease Therapeutics. Thus with the growth in treatments the global homocystinuria market is expected to flourish in the upcoming years.
Region Outlook
Based on the regions, North America had the highest share in the homocystinuria market in the year 2021. In the last few years, there has been a rising awareness about the rare disease and its treatments amongst a huge population. In United States, new born screening for homocystinuria is been carried out on large scale so that effective treatments can be provided to the infants. Moreover, the leading players in the region are looking forward to invest into clinical trials and treatments of homocystinuria. For instance, in 2021, Aeglea Biotherapeutics, Inc. is developing new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases. AGLE-177 for the treatment of homocystinuria has markedly elevated plasma homocysteine levels lead to a wide range of life-altering complications and reduced life expectancy in people with homocystinuria. Thus with such advancements the homocystinuria market is growing in the North America region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global homocystinuria market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global homocystinuria market are listed below:
- Aeglea BioTherapeutics
- AGRANA Beteiligungs-AG
- AMINO GmbH
- Chemkart
- MYLAN N.V
- Rare Disease Therapeutics, Inc.
- Recordati Rare Diseases Inc
- SVB Financial Group
- Other Industry Participants
Global Homocystinuria market
By Symptoms
- Myopia
- Abnormal blood clots
- Osteoporosis
- Intellectual disabilities
- Seizures
- Others
By Diagnosis
- Blood and Urine testing
- Genetic Testing
- Liver Biopsy
- X-rays
- Others
By Drug Treatment
- Pyridoxine
- Betaine
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2020
1.2.2.
Base
Year: 2021
1.2.3.
Forecast
Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Homocystinuria Market
6.
Market
Synopsis: Homocystinuria Market
7.
Homocystinuria
Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Homocystinuria Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Homocystinuria Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Homocystinuria Market
8.
Global
Homocystinuria Market Analysis and Forecasts, 2022 – 2030
8.1.
Overview
8.1.1.
Global
Homocystinuria Market Revenue (US$ Mn)
8.2.
Global
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
8.2.1.
Myopia
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2.
Abnormal
blood clots
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3.
Osteoporosis
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4.
Intellectual
disabilities
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5.
Seizures
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6.
Others
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.3.
Key
Segment for Channeling Investments
8.3.1.
By
Symptoms
9.
Global
Homocystinuria Market Analysis and Forecasts, 2022 – 2030
9.1.
Overview
9.2.
Global
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
9.2.1.
Blood
and Urine testing
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2.
Genetic
Testing
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3.
Liver
Biopsy
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4.
X-rays
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5.
Others
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Diagnosis
10. Global Homocystinuria Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Homocystinuria Market Revenue (US$ Mn)
and Forecasts, By Drug Treatment
10.2.1. Pyridoxine
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Betaine
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Others
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Drug Treatment
11. North America Homocystinuria Market Analysis
and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Homocystinuria Market Revenue
(US$ Mn)
11.2. North America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Symptoms
11.2.1. Myopia
11.2.2. Abnormal blood clots
11.2.3. Osteoporosis
11.2.4. Intellectual disabilities
11.2.5. Seizures
11.2.6. Others
11.3. North America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
11.3.1. Blood and Urine testing
11.3.2. Genetic Testing
11.3.3. Liver Biopsy
11.3.4. X-rays
11.3.5. Others
11.4. North America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Drug Treatment
11.4.1. Pyridoxine
11.4.2. Betaine
11.4.3. Others
11.5. North America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1.
U.S
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
11.5.1.1.1.
Myopia
11.5.1.1.2.
Abnormal
blood clots
11.5.1.1.3.
Osteoporosis
11.5.1.1.4.
Intellectual
disabilities
11.5.1.1.5.
Seizures
11.5.1.1.6.
Others
11.5.1.2.
U.S
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.1.2.1.
Blood
and Urine testing
11.5.1.2.2.
Genetic
Testing
11.5.1.2.3.
Liver Biopsy
11.5.1.2.4.
X-rays
11.5.1.2.5.
Others
11.5.1.3.
U.S
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
11.5.1.3.1.
Pyridoxine
11.5.1.3.2.
Betaine
11.5.1.3.3.
Others
11.5.2. Canada
11.5.2.1.
Canada
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
11.5.2.1.1.
Myopia
11.5.2.1.2.
Abnormal
blood clots
11.5.2.1.3.
Osteoporosis
11.5.2.1.4.
Intellectual
disabilities
11.5.2.1.5.
Seizures
11.5.2.1.6.
Others
11.5.2.2.
Canada
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.2.2.1.
Blood
and Urine testing
11.5.2.2.2.
Genetic
Testing
11.5.2.2.3.
Liver
Biopsy
11.5.2.2.4.
X-rays
11.5.2.2.5.
Others
11.5.2.3.
Canada
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
11.5.2.3.1.
Pyridoxine
11.5.2.3.2.
Betaine
11.5.2.3.3.
Others
11.5.3. Mexico
11.5.3.1.
Mexico
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
11.5.3.1.1.
Myopia
11.5.3.1.2.
Abnormal
blood clots
11.5.3.1.3.
Osteoporosis
11.5.3.1.4.
Intellectual
disabilities
11.5.3.1.5.
Seizures
11.5.3.1.6.
Others
11.5.3.2.
Mexico
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
11.5.3.2.1.
Blood
and Urine testing
11.5.3.2.2.
Genetic
Testing
11.5.3.2.3.
Liver
Biopsy
11.5.3.2.4.
X-rays
11.5.3.2.5.
Others
11.5.3.3.
Mexico
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
11.5.3.3.1.
Pyridoxine
11.5.3.3.2.
Betaine
11.5.3.3.3.
Others
11.5.4. Rest of North America
11.5.4.1.
Rest of
North America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
11.5.4.1.1.
Myopia
11.5.4.1.2.
Abnormal
blood clots
11.5.4.1.3.
Osteoporosis
11.5.4.1.4.
Intellectual
disabilities
11.5.4.1.5.
Seizures
11.5.4.1.6.
Others
11.5.4.2.
Rest of
North America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
11.5.4.2.1.
Blood
and Urine testing
11.5.4.2.2.
Genetic
Testing
11.5.4.2.3.
Liver
Biopsy
11.5.4.2.4.
X-rays
11.5.4.2.5.
Others
11.5.4.3.
Rest of
North America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug
Treatment
11.5.4.3.1.
Pyridoxine
11.5.4.3.2.
Betaine
11.5.4.3.3.
Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Symptoms
11.6.3. By Diagnosis
11.6.4. By Drug Treatment
12. Europe Homocystinuria Market Analysis and
Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe Homocystinuria Market Revenue (US$ Mn)
12.2. Europe Homocystinuria Market Revenue (US$ Mn)
and Forecasts, By Symptoms
12.2.1. Myopia
12.2.2. Abnormal blood clots
12.2.3. Osteoporosis
12.2.4. Intellectual disabilities
12.2.5. Seizures
12.2.6. Others
12.3. Europe Homocystinuria Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
12.3.1. Blood and Urine testing
12.3.2. Genetic Testing
12.3.3. Liver Biopsy
12.3.4. X-rays
12.3.5. Others
12.4. Europe Homocystinuria Market Revenue (US$ Mn)
and Forecasts, By Drug Treatment
12.4.1. Pyridoxine
12.4.2. Betaine
12.4.3. Others
12.5. Europe Homocystinuria Market Revenue (US$ Mn)
and Forecasts, By Country
12.5.1. France
12.5.1.1.
France
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.1.1.1.
Myopia
12.5.1.1.2.
Abnormal
blood clots
12.5.1.1.3.
Osteoporosis
12.5.1.1.4.
Intellectual
disabilities
12.5.1.1.5.
Seizures
12.5.1.1.6.
Others
12.5.1.2.
France
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.1.2.1.
Blood
and Urine testing
12.5.1.2.2.
Genetic
Testing
12.5.1.2.3.
Liver
Biopsy
12.5.1.2.4.
X-rays
12.5.1.2.5.
Others
12.5.1.3.
France
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.1.3.1.
Pyridoxine
12.5.1.3.2.
Betaine
12.5.1.3.3.
Others
12.5.2. The UK
12.5.2.1.
The UK
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.2.1.1.
Myopia
12.5.2.1.2.
Abnormal
blood clots
12.5.2.1.3.
Osteoporosis
12.5.2.1.4.
Intellectual
disabilities
12.5.2.1.5.
Seizures
12.5.2.1.6.
Others
12.5.2.2.
The UK
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.2.2.1.
Blood
and Urine testing
12.5.2.2.2.
Genetic
Testing
12.5.2.2.3.
Liver
Biopsy
12.5.2.2.4.
X-rays
12.5.2.2.5.
Others
12.5.2.3.
The UK
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.2.3.1.
Pyridoxine
12.5.2.3.2.
Betaine
12.5.2.3.3.
Others
12.5.3. Spain
12.5.3.1.
Spain
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.3.1.1.
Myopia
12.5.3.1.2.
Abnormal
blood clots
12.5.3.1.3.
Osteoporosis
12.5.3.1.4.
Intellectual
disabilities
12.5.3.1.5.
Seizures
12.5.3.1.6.
Others
12.5.3.2.
Spain
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.3.2.1.
Blood
and Urine testing
12.5.3.2.2.
Genetic
Testing
12.5.3.2.3.
Liver
Biopsy
12.5.3.2.4.
X-rays
12.5.3.2.5.
Others
12.5.3.3.
Spain
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.3.3.1.
Pyridoxine
12.5.3.3.2.
Betaine
12.5.3.3.3.
Others
12.5.4. Germany
12.5.4.1.
Germany
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.4.1.1.
Myopia
12.5.4.1.2.
Abnormal
blood clots
12.5.4.1.3.
Osteoporosis
12.5.4.1.4.
Intellectual
disabilities
12.5.4.1.5.
Seizures
12.5.4.1.6.
Others
12.5.4.2.
Germany
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.4.2.1.
Blood
and Urine testing
12.5.4.2.2.
Genetic
Testing
12.5.4.2.3.
Liver
Biopsy
12.5.4.2.4.
X-rays
12.5.4.2.5.
Others
12.5.4.3.
Germany
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.4.3.1.
Pyridoxine
12.5.4.3.2.
Betaine
12.5.4.3.3.
Others
12.5.5. Italy
12.5.5.1.
Italy
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.5.1.1.
Myopia
12.5.5.1.2.
Abnormal
blood clots
12.5.5.1.3.
Osteoporosis
12.5.5.1.4.
Intellectual
disabilities
12.5.5.1.5.
Seizures
12.5.5.1.6.
Others
12.5.5.2.
Italy
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.5.2.1.
Blood and
Urine testing
12.5.5.2.2.
Genetic
Testing
12.5.5.2.3.
Liver
Biopsy
12.5.5.2.4.
X-rays
12.5.5.2.5.
Others
12.5.5.3.
Italy
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.5.3.1.
Pyridoxine
12.5.5.3.2.
Betaine
12.5.5.3.3.
Others
12.5.6. Nordic Countries
12.5.6.1.
Nordic
Countries Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.6.1.1.
Myopia
12.5.6.1.2.
Abnormal
blood clots
12.5.6.1.3.
Osteoporosis
12.5.6.1.4.
Intellectual
disabilities
12.5.6.1.5.
Seizures
12.5.6.1.6.
Others
12.5.6.2.
Nordic
Countries Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.6.2.1.
Blood
and Urine testing
12.5.6.2.2.
Genetic
Testing
12.5.6.2.3.
Liver
Biopsy
12.5.6.2.4.
X-rays
12.5.6.2.5.
Others
12.5.6.3.
Nordic
Countries Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug
Treatment
12.5.6.3.1.
Pyridoxine
12.5.6.3.2.
Betaine
12.5.6.3.3.
Others
12.5.6.4.
Nordic
Countries Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.
Denmark
12.5.6.4.2.
Finland
12.5.6.4.3.
Iceland
12.5.6.4.4.
Sweden
12.5.6.4.5.
Norway
12.5.7. Benelux Union
12.5.7.1.
Benelux
Union Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.7.1.1.
Myopia
12.5.7.1.2.
Abnormal
blood clots
12.5.7.1.3.
Osteoporosis
12.5.7.1.4.
Intellectual
disabilities
12.5.7.1.5.
Seizures
12.5.7.1.6.
Others
12.5.7.2.
Benelux
Union Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.7.2.1.
Blood
and Urine testing
12.5.7.2.2.
Genetic
Testing
12.5.7.2.3.
Liver
Biopsy
12.5.7.2.4.
X-rays
12.5.7.2.5.
Others
12.5.7.3.
Benelux
Union Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.7.3.1.
Pyridoxine
12.5.7.3.2.
Betaine
12.5.7.3.3.
Others
12.5.7.4.
Benelux
Union Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.
Belgium
12.5.7.4.2.
The
Netherlands
12.5.7.4.3.
Luxembourg
12.5.8. Rest of Europe
12.5.8.1.
Rest of
Europe Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
12.5.8.1.1.
Myopia
12.5.8.1.2.
Abnormal
blood clots
12.5.8.1.3.
Osteoporosis
12.5.8.1.4.
Intellectual
disabilities
12.5.8.1.5.
Seizures
12.5.8.1.6.
Others
12.5.8.2.
Rest of
Europe Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
12.5.8.2.1.
Blood
and Urine testing
12.5.8.2.2.
Genetic
Testing
12.5.8.2.3.
Liver
Biopsy
12.5.8.2.4.
X-rays
12.5.8.2.5.
Others
12.5.8.3.
Rest of
Europe Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
12.5.8.3.1.
Pyridoxine
12.5.8.3.2.
Betaine
12.5.8.3.3.
Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Symptoms
12.6.3. By Diagnosis
12.6.4. By Drug Treatment
13. Asia Pacific Homocystinuria Market Analysis
and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Homocystinuria Market Revenue
(US$ Mn)
13.2. Asia Pacific Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Symptoms
13.2.1. Myopia
13.2.2. Abnormal blood clots
13.2.3. Osteoporosis
13.2.4. Intellectual disabilities
13.2.5. Seizures
13.2.6. Others
13.3. Asia Pacific Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
13.3.1. Blood and Urine testing
13.3.2. Genetic Testing
13.3.3. Liver Biopsy
13.3.4. X-rays
13.3.5. Others
13.4. Asia Pacific Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Drug Treatment
13.4.1. Pyridoxine
13.4.2. Betaine
13.4.3. Others
13.5. Asia Pacific Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1.
China
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.1.1.1.
Myopia
13.5.1.1.2.
Abnormal
blood clots
13.5.1.1.3.
Osteoporosis
13.5.1.1.4.
Intellectual
disabilities
13.5.1.1.5.
Seizures
13.5.1.1.6.
Others
13.5.1.2.
China
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.1.2.1.
Blood
and Urine testing
13.5.1.2.2.
Genetic
Testing
13.5.1.2.3.
Liver
Biopsy
13.5.1.2.4.
X-rays
13.5.1.2.5.
Others
13.5.1.3.
China
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.1.3.1.
Pyridoxine
13.5.1.3.2.
Betaine
13.5.1.3.3.
Others
13.5.2. Japan
13.5.2.1.
Japan
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.2.1.1.
Myopia
13.5.2.1.2.
Abnormal
blood clots
13.5.2.1.3.
Osteoporosis
13.5.2.1.4.
Intellectual
disabilities
13.5.2.1.5.
Seizures
13.5.2.1.6.
Others
13.5.2.2.
Japan
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.2.2.1.
Blood
and Urine testing
13.5.2.2.2.
Genetic
Testing
13.5.2.2.3.
Liver
Biopsy
13.5.2.2.4.
X-rays
13.5.2.2.5.
Others
13.5.2.3.
Japan
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.2.3.1.
Pyridoxine
13.5.2.3.2.
Betaine
13.5.2.3.3.
Others
13.5.3. India
13.5.3.1.
India
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.3.1.1.
Myopia
13.5.3.1.2.
Abnormal
blood clots
13.5.3.1.3.
Osteoporosis
13.5.3.1.4.
Intellectual
disabilities
13.5.3.1.5.
Seizures
13.5.3.1.6.
Others
13.5.3.2.
India
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.3.2.1.
Blood
and Urine testing
13.5.3.2.2.
Genetic
Testing
13.5.3.2.3.
Liver
Biopsy
13.5.3.2.4.
X-rays
13.5.3.2.5.
Others
13.5.3.3.
India
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.3.3.1.
Pyridoxine
13.5.3.3.2.
Betaine
13.5.3.3.3.
Others
13.5.4. New Zealand
13.5.4.1.
New
Zealand Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.4.1.1.
Myopia
13.5.4.1.2.
Abnormal
blood clots
13.5.4.1.3.
Osteoporosis
13.5.4.1.4.
Intellectual
disabilities
13.5.4.1.5.
Seizures
13.5.4.1.6.
Others
13.5.4.2.
New
Zealand Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.4.2.1.
Blood
and Urine testing
13.5.4.2.2.
Genetic
Testing
13.5.4.2.3.
Liver
Biopsy
13.5.4.2.4.
X-rays
13.5.4.2.5.
Others
13.5.4.3.
New
Zealand Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.4.3.1.
Pyridoxine
13.5.4.3.2.
Betaine
13.5.4.3.3.
Others
13.5.5. Australia
13.5.5.1.
Australia
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.5.1.1.
Myopia
13.5.5.1.2.
Abnormal
blood clots
13.5.5.1.3.
Osteoporosis
13.5.5.1.4.
Intellectual
disabilities
13.5.5.1.5.
Seizures
13.5.5.1.6.
Others
13.5.5.2.
Australia
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.5.2.1.
Blood
and Urine testing
13.5.5.2.2.
Genetic
Testing
13.5.5.2.3.
Liver
Biopsy
13.5.5.2.4.
X-rays
13.5.5.2.5.
Others
13.5.5.3.
Australia
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.5.3.1.
Pyridoxine
13.5.5.3.2.
Betaine
13.5.5.3.3.
Others
13.5.6. South Korea
13.5.6.1.
South
Korea Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.6.1.1.
Myopia
13.5.6.1.2.
Abnormal
blood clots
13.5.6.1.3.
Osteoporosis
13.5.6.1.4.
Intellectual
disabilities
13.5.6.1.5.
Seizures
13.5.6.1.6.
Others
13.5.6.2.
South
Korea Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.6.2.1.
Blood
and Urine testing
13.5.6.2.2.
Genetic
Testing
13.5.6.2.3.
Liver
Biopsy
13.5.6.2.4.
X-rays
13.5.6.2.5.
Others
13.5.6.3.
South
Korea Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.6.3.1.
Pyridoxine
13.5.6.3.2.
Betaine
13.5.6.3.3.
Others
13.5.7. Southeast Asia
13.5.7.1.
Southeast
Asia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.7.1.1.
Myopia
13.5.7.1.2.
Abnormal
blood clots
13.5.7.1.3.
Osteoporosis
13.5.7.1.4.
Intellectual
disabilities
13.5.7.1.5.
Seizures
13.5.7.1.6.
Others
13.5.7.2.
Southeast
Asia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.7.2.1.
Blood
and Urine testing
13.5.7.2.2.
Genetic
Testing
13.5.7.2.3.
Liver
Biopsy
13.5.7.2.4.
X-rays
13.5.7.2.5.
Others
13.5.7.3.
Southeast
Asia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
13.5.7.3.1.
Pyridoxine
13.5.7.3.2.
Betaine
13.5.7.3.3.
Others
13.5.7.4.
Southeast
Asia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.
Indonesia
13.5.7.4.2.
Thailand
13.5.7.4.3.
Malaysia
13.5.7.4.4.
Singapore
13.5.7.4.5.
Rest of
Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1.
Rest of
Asia Pacific Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
13.5.8.1.1.
Myopia
13.5.8.1.2.
Abnormal
blood clots
13.5.8.1.3.
Osteoporosis
13.5.8.1.4.
Intellectual
disabilities
13.5.8.1.5.
Seizures
13.5.8.1.6.
Others
13.5.8.2.
Rest of
Asia Pacific Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.5.8.2.1.
Blood
and Urine testing
13.5.8.2.2.
Genetic
Testing
13.5.8.2.3.
Liver
Biopsy
13.5.8.2.4.
X-rays
13.5.8.2.5.
Others
13.5.8.3.
Rest of
Asia Pacific Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug
Treatment
13.5.8.3.1.
Pyridoxine
13.5.8.3.2.
Betaine
13.5.8.3.3.
Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Symptoms
13.6.3. By Diagnosis
13.6.4. By Drug Treatment
14. Middle East and Africa Homocystinuria Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Homocystinuria Market
Revenue (US$ Mn)
14.2. Middle East and Africa Homocystinuria Market
Revenue (US$ Mn) and Forecasts, By Symptoms
14.2.1. Myopia
14.2.2. Abnormal blood clots
14.2.3. Osteoporosis
14.2.4. Intellectual disabilities
14.2.5. Seizures
14.2.6. Others
14.3. Middle East and Africa Homocystinuria Market
Revenue (US$ Mn) and Forecasts, By Diagnosis
14.3.1. Blood and Urine testing
14.3.2. Genetic Testing
14.3.3. Liver Biopsy
14.3.4. X-rays
14.3.5. Others
14.4. Middle East and Africa Homocystinuria Market
Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.4.1. Pyridoxine
14.4.2. Betaine
14.4.3. Others
14.5. Middle East and Africa Homocystinuria Market
Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1.
Saudi
Arabia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.5.1.1.1.
Myopia
14.5.1.1.2.
Abnormal
blood clots
14.5.1.1.3.
Osteoporosis
14.5.1.1.4.
Intellectual
disabilities
14.5.1.1.5.
Seizures
14.5.1.1.6.
Others
14.5.1.2.
Saudi
Arabia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.1.2.1.
Blood
and Urine testing
14.5.1.2.2.
Genetic
Testing
14.5.1.2.3.
Liver
Biopsy
14.5.1.2.4.
X-rays
14.5.1.2.5.
Others
14.5.1.3.
Saudi
Arabia Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.5.1.3.1.
Pyridoxine
14.5.1.3.2.
Betaine
14.5.1.3.3.
Others
14.5.2. UAE
14.5.2.1.
UAE
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.5.2.1.1.
Myopia
14.5.2.1.2.
Abnormal
blood clots
14.5.2.1.3.
Osteoporosis
14.5.2.1.4.
Intellectual
disabilities
14.5.2.1.5.
Seizures
14.5.2.1.6.
Others
14.5.2.2.
UAE
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.2.2.1.
Blood
and Urine testing
14.5.2.2.2.
Genetic
Testing
14.5.2.2.3.
Liver
Biopsy
14.5.2.2.4.
X-rays
14.5.2.2.5.
Others
14.5.2.3.
UAE
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.5.2.3.1.
Pyridoxine
14.5.2.3.2.
Betaine
14.5.2.3.3.
Others
14.5.3. Egypt
14.5.3.1.
Egypt
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.5.3.1.1.
Myopia
14.5.3.1.2.
Abnormal
blood clots
14.5.3.1.3.
Osteoporosis
14.5.3.1.4.
Intellectual
disabilities
14.5.3.1.5.
Seizures
14.5.3.1.6.
Others
14.5.3.2.
Egypt
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.3.2.1.
Blood
and Urine testing
14.5.3.2.2.
Genetic
Testing
14.5.3.2.3.
Liver
Biopsy
14.5.3.2.4.
X-rays
14.5.3.2.5.
Others
14.5.3.3.
Egypt
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.5.3.3.1.
Pyridoxine
14.5.3.3.2.
Betaine
14.5.3.3.3.
Others
14.5.4. Kuwait
14.5.4.1.
Kuwait
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.5.4.1.1.
Myopia
14.5.4.1.2.
Abnormal
blood clots
14.5.4.1.3.
Osteoporosis
14.5.4.1.4.
Intellectual
disabilities
14.5.4.1.5.
Seizures
14.5.4.1.6.
Others
14.5.4.2.
Kuwait
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.4.2.1.
Blood
and Urine testing
14.5.4.2.2.
Genetic
Testing
14.5.4.2.3.
Liver
Biopsy
14.5.4.2.4.
X-rays
14.5.4.2.5.
Others
14.5.4.3.
Kuwait
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.5.4.3.1.
Pyridoxine
14.5.4.3.2.
Betaine
14.5.4.3.3.
Others
14.5.5. South Africa
14.5.5.1.
South Africa
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
14.5.5.1.1.
Myopia
14.5.5.1.2.
Abnormal
blood clots
14.5.5.1.3.
Osteoporosis
14.5.5.1.4.
Intellectual
disabilities
14.5.5.1.5.
Seizures
14.5.5.1.6.
Others
14.5.5.2.
South
Africa Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.5.5.2.1.
Blood
and Urine testing
14.5.5.2.2.
Genetic
Testing
14.5.5.2.3.
Liver
Biopsy
14.5.5.2.4.
X-rays
14.5.5.2.5.
Others
14.5.5.3.
South
Africa Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
14.5.5.3.1.
Pyridoxine
14.5.5.3.2.
Betaine
14.5.5.3.3.
Others
14.5.6. Rest of Middle East & Africa
14.5.6.1.
Rest of
Middle East & Africa Homocystinuria Market Revenue (US$ Mn) and Forecasts,
By Symptoms
14.5.6.1.1.
Myopia
14.5.6.1.2.
Abnormal
blood clots
14.5.6.1.3.
Osteoporosis
14.5.6.1.4.
Intellectual
disabilities
14.5.6.1.5.
Seizures
14.5.6.1.6.
Others
14.5.6.2.
Rest of
Middle East & Africa Homocystinuria Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.5.6.2.1.
Blood
and Urine testing
14.5.6.2.2.
Genetic
Testing
14.5.6.2.3.
Liver
Biopsy
14.5.6.2.4.
X-rays
14.5.6.2.5.
Others
14.5.6.3.
Rest of
Middle East & Africa Homocystinuria Market Revenue (US$ Mn) and Forecasts,
By Drug Treatment
14.5.6.3.1.
Pyridoxine
14.5.6.3.2.
Betaine
14.5.6.3.3.
Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Symptoms
14.6.3. By Diagnosis
14.6.4. By Drug Treatment
15. Latin America Homocystinuria Market Analysis
and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Homocystinuria Market Revenue
(US$ Mn)
15.2. Latin America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Symptoms
15.2.1. Myopia
15.2.2. Abnormal blood clots
15.2.3. Osteoporosis
15.2.4. Intellectual disabilities
15.2.5. Seizures
15.2.6. Others
15.3. Latin America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
15.3.1. Blood and Urine testing
15.3.2. Genetic Testing
15.3.3. Liver Biopsy
15.3.4. X-rays
15.3.5. Others
15.4. Latin America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Drug Treatment
15.4.1. Pyridoxine
15.4.2. Betaine
15.4.3. Others
15.5. Latin America Homocystinuria Market Revenue
(US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1.
Brazil
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.5.1.1.1.
Myopia
15.5.1.1.2.
Abnormal
blood clots
15.5.1.1.3.
Osteoporosis
15.5.1.1.4.
Intellectual
disabilities
15.5.1.1.5.
Seizures
15.5.1.1.6.
Others
15.5.1.2.
Brazil
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.5.1.2.1.
Blood
and Urine testing
15.5.1.2.2.
Genetic
Testing
15.5.1.2.3.
Liver
Biopsy
15.5.1.2.4.
X-rays
15.5.1.2.5.
Others
15.5.1.3.
Brazil
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
15.5.1.3.1.
Pyridoxine
15.5.1.3.2.
Betaine
15.5.1.3.3.
Others
15.5.2. Argentina
15.5.2.1.
Argentina
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.5.2.1.1.
Myopia
15.5.2.1.2.
Abnormal
blood clots
15.5.2.1.3.
Osteoporosis
15.5.2.1.4.
Intellectual
disabilities
15.5.2.1.5.
Seizures
15.5.2.1.6.
Others
15.5.2.2.
Argentina
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.5.2.2.1.
Blood
and Urine testing
15.5.2.2.2.
Genetic
Testing
15.5.2.2.3.
Liver
Biopsy
15.5.2.2.4.
X-rays
15.5.2.2.5.
Others
15.5.2.3.
Argentina
Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug Treatment
15.5.2.3.1.
Pyridoxine
15.5.2.3.2.
Betaine
15.5.2.3.3.
Others
15.5.3. Rest of Latin America
15.5.3.1.
Rest of
Latin America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Symptoms
15.5.3.1.1.
Myopia
15.5.3.1.2.
Abnormal
blood clots
15.5.3.1.3.
Osteoporosis
15.5.3.1.4.
Intellectual
disabilities
15.5.3.1.5.
Seizures
15.5.3.1.6.
Others
15.5.3.2.
Rest of
Latin America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.5.3.2.1.
Blood
and Urine testing
15.5.3.2.2.
Genetic
Testing
15.5.3.2.3.
Liver
Biopsy
15.5.3.2.4.
X-rays
15.5.3.2.5.
Others
15.5.3.3.
Rest of
Latin America Homocystinuria Market Revenue (US$ Mn) and Forecasts, By Drug
Treatment
15.5.3.3.1.
Pyridoxine
15.5.3.3.2.
Betaine
15.5.3.3.3.
Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Symptoms
15.6.3. By Diagnosis
15.6.4. By Drug Treatment
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2021
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Aeglea BioTherapeutics
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. AGRANA Beteiligungs-AG
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. AMINO GmbH
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Chemkart
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. MYLAN N.V
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Rare Disease Therapeutics, Inc.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Recordati Rare Diseases Inc
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. SVB Financial Group.
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7.
Business
Strategies
17.9. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
